Axogen/AXGN

$10.51

-1.5%
-
1D1W1MYTD1YMAX

About Axogen

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Axotouch Two-Point Discriminator. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.

Ticker

AXGN

Sector

Tervishoid

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Karen Zaderej

Employees

394

Headquarters

Alachua, United States

Axogen Metrics

BasicAdvanced
$449.81M
Market cap
-
P/E ratio
-$0.54
EPS
1.06
Beta
-
Dividend rate

What the Analysts think about Axogen

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
16.56% upside
High $17.00
Low $9.00
$10.51
Current price
$12.25
Average price target

Axogen Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-9.7% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$41.2M
8.14%
Net income
$-4M
-39.39%
Profit margin
-9.7%
-44%

Axogen Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 116%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.03
-$0.10
-$0.03
$0.01
-
Expected
-$0.11
-$0.15
-$0.13
-$0.06
-$0.10
Surprise
-73.57%
-31.03%
-76.92%
-116%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Axogen stock

Buy or sell Axogen stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing